Search Abstracts Program

Session 64   Poster Session Therapeutic Drug Monitoring 4:30-6:30 pm 4E-F

Click on the to view the poster for an abstract.

449-W.	Influence of Binding to Human Plasma Proteins by Protease Inhibitors may be Overestimated in Current IQ Models M. P. de Béthune*1, D. Xie2, H. Azijn1, P. Wigerinck1, R. Hoetelmans1, and R. Pauwels1 1Tibotec-Virco, Mechelen, Belgium and 2Tibotec Inc., Rockville, MD Add to Itinerary
450-W.	The Interim Analysis of a Phase IV Randomised, Open-Label, Multicentre Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir (800/100 mg BID) vs Saquinavir/Ritonavir (1000/100 mg MID) in Adult HIV-1 Infection: MaxCmin1 Trial A. Castagna*, U. B. Dragsted, J-P. Chave, A. Rieger, G. Carosi, S. van der Geest, H. Nielsen, and J. D. Lundgren for the MaxCmin1 Trial Group Co-ordinating Office for the MaxCmin1 Trial, Copenhagen HIV Programme (CHIP), Denmark Add to Itinerary
451-W.	Pilot Study of Saquinavir-SGC (Fortovase, SQV) 1000 mg Twice Daily and Lopinavir/Ritonavir (Kaletra, LPV/r) in Protease Inhibitor-Experienced HIV+ Individuals: Dose Escalation and Combined Normalized Inhibitory Quotient (cNIQ) J. Hellinger*1, A. B. Morris1, S. Piscitelli2, D. Gordon1, K. Foy1, L. Jackson-Pope1, D. Cordeiro1, M. Peeters2, R. Hoetelmans2, P. J. de Caprariis3, and C. Cohen1 1Comm. Res. Initiative, Boston and Springfield, MA; 2Virco, Rockville, MD, and Mechelen, Belgium; and 3Roche Labs., Nutley, NJ Add to Itinerary
452-W.	Monitoring Intracellular Triphosphorylated Anabolites of Didanosine EC (ddI) and Stavudine (d4T): Results of a Pilot Clinical Study in HIV-Infected Patients F. Becher1, R. Landman2, A. Canestri2, S. Mboup3, C. Toure Kane3, F. Liegeois4, M. Vray5, C. Dalban5, M. H. Prevot6, G. Leleu*6, and H. Benech1 1CEA, Gif/Yvette, France; 2IMEA, Paris, France; 3PLNS-Dakar, Senegal; 4IRD U36, Montpellier, France; 5INSERM SC4, Paris, France; and 6Bristol-Myers Squibb, Paris-La Defense, France Add to Itinerary
453-W.	Pharmacokinetics and Genotyping in Lopinavir Recipients with Prior PI Failure M. Boffito*1,2, I. Arnaudo1, S. Bonora1, A. Sinicco1, R. Raiteri1, P. Hoggard2, D. Back2, and G. Di Perri1 1Univ. of Torino, Italy and 2Univ. of Liverpool, UK Add to Itinerary
454-W.	Attainment of Higher Efavirenz Plasma Levels Allow to Regain Complete Virus Suppression in Patients Carrying NNRTI Resistance D. González de Requena*, O. Gallego, C. Briones, I. Jiménez-Nácher, and V. Soriano Inst. de Salud Carlos III, Madrid, Spain Add to Itinerary
455-W.	Virological Failure Is Associated with Decreased 3TC Triphosphate (3TCTP) and Ratio of 3TCTP/Endogenous Deoxycytidine Triphosphate in HIV-Infected Individuals in a Clinical Setting P. Hoggard*1, S. Kewn1, J. Lloyd1, S. Sales1, E. Wilkins2, B. Maher1, E. Meaden1, L. Almond1, T. Jones3, D. Pillay4, C. Sabin5, S. Khoo1, and D. Back1 1Univ. of Liverpool; 2Northern Manchester Gen. Hosp.; 3GlaxoSmithKline; 4Univ. of Birmingham Med. Sch.; and 5Royal Free Hosp., London, UK Add to Itinerary

---